+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component Application, and End User - Global Forecast to 2031- Product Image
Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component Application, and End User - Global Forecast to 2031- Product Image
Sale

Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component Application, and End User - Global Forecast to 2031

  • PDF Icon

    Report

  • 254 Pages
  • August 2024
  • Region: Global
  • Meticulous Market Research Pvt. Ltd.
  • ID: 4755940
UP TO OFF until Jan 10th 2025
Description Jump to:

Real-world Evidence (RWE) Solutions Market Worth $4.9 billion by 2029

Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User - Global Forecast to 2031
The global RWE solutions market was valued at $2.62 billion in 2023. This market is expected to reach $6.37 billion by 2031 from an estimated $2.94 billion in 2024, at a CAGR of 11.7% during the forecast period of 2024-2031.

Following a comprehensive primary & secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by the growing incidence of chronic diseases, delays in drug development and the consequent increase in development costs, the rising focus on personalized healthcare, a shift toward value-based care, and the growing adoption of real-world evidence solutions in drug development & commercialization. For instance, IQVIA introduced One Home for Sites in June 2024. This digital platform serves as a dashboard for all the essential systems and tasks needed by a clinical research site to conduct clinical trials.

Furthermore, emerging economies and a rising focus on end-to-end RWE services provide significant growth opportunities for the real-world solutions market. However, the market's expansion may be constrained by the unwillingness to rely on real-world research and the absence of quality control in data collection. Additionally, the lack of standardized methodologies for developing RWE and data privacy and security concerns pose a major challenge for the players operating in this market.

Among components, in 2024, the datasets segment is expected to account for the largest share of the RWE solutions market. RWE datasets originate from a range of sources related to patient outcomes in diverse populations in real-world contexts. With regard to unfulfilled needs and the financial and clinical effects on patients and healthcare systems, this solution offers insightful information. Additionally, it bases results on far larger data sets, lower expenses, and more effective clinical trial management.

Among applications, in 2024, the market access & reimbursement/coverage decisions segment is expected to account for the largest share of the RWE solutions market. Using predictive analysis and data-driven insights, RWE solutions for market access enable a comprehensive assessment of a medical product's efficacy and value, which can support value-based pricing strategies and result in favorable reimbursement outcomes. The significant market share is ascribed to several factors, including escalating healthcare expenses, growing regulatory body acceptance of RWE, expanding significance of clinical value evidence in coverage determinations, and the availability of supplementary data regarding treatment efficacy in routine care environments and heterogeneous patient cohorts.

Among end users, in 2024, the pharmaceutical, biotechnology, and medical device companies segment is expected to account for the largest share of the RWE solutions market. Several variables, including the growing use of RWE to gather real-time post-trial data about medications, monitor drug reactions, and prove the worth of newly created therapies outside of clinical trials, as well as expedited drug trials and extended approvals, are responsible for a substantial share of the segment.

An in-depth analysis of the global RWE solutions market's geographical scenario provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America). It covers the major countries in each region.

In 2024, North America is expected to account for the largest share of the global RWE solutions market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The substantial share of North America can be attributed to various factors, including the rising incidence of chronic illnesses, stricter guidelines for medication approvals, the 21st Century Cures Act, the broad accessibility of electronic datasets, a firmly established healthcare industry, and the growing application of big data in healthcare.

The key players operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), Elevance Health, Inc. (U.S.), ICON plc (Ireland), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Revvity, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Oracle Corporation (U.S.), SAS Institute Inc. (U.S.), Parexel International Corporation (U.S.), and HealthVerity, Inc. (U.S.).

Scope of the Report:

Real-world Evidence Solutions Market Assessment - by Component

  • Datasets
  • Disparate Datasets
  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Genomics Data
  • Other Disparate Datasets
  • Integrated Datasets
  • Consulting Services
Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media.

Real-world Evidence Solutions Market Assessment - by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Other Applications
Note: 1) Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases.

2) Other Applications include regulatory and clinical decision-making.

Real-world Evidence Solutions Market Assessment - by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users
Note: Other end users include academic & research institutions, patient advocacy groups, regulators, and health technology assessment agencies.

Real-world Evidence Solutions Market Assessment - by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Switzerland
  • Belgium
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Singapore
  • Australia
  • Rest of Asia-Pacific (RoAPAC)
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
  • Middle East & Africa

Table of Contents

1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing & Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions For the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Drivers
4.2.1.1.1. Rising Focus on Personalized Healthcare
4.2.1.1.2. Delays in Drug Development and the Consequent Increase in Development Costs
4.2.1.1.3. Growing Incidence of Chronic Diseases
4.2.1.1.4. Shift toward Value-based Care
4.2.1.1.5. Rapidly Growing Big Data in the Healthcare Sector
4.2.1.2. Restraints
4.2.1.2.1. Reluctance to Rely on Real-world Studies
4.2.1.3. Opportunities
4.2.1.3.1. Emerging economies
4.2.1.3.2. Rising Focus on End-to-End RWE Services
4.2.1.4. Challenges
4.2.1.4.1. Lack of Standardized Methodologies for Developing RWE
4.2.2. Factors Analysis
4.3. Key Market Trends
4.3.1. The Incorporation of Artificial Intelligence (AI) in the RWE Industry
4.3.1.1. The Adoption of AI Technologies is Growing in the Following Areas:
4.3.1.1.1. Clinical Trials Design
4.3.1.1.2. Modeling and Forecasting Patient Enrichment & Recruitment
4.3.1.1.3. Selecting Investigator Site
4.3.1.1.4. Patient Monitoring & Managing and Medication Adherence & Retention
4.3.1.1.5. AI-enabled Clinical Trial Analytics
4.3.1.1.6. Outsourcing Essential AI Solutions via Strategic Partnerships & Collaborations
4.3.1.1.7. Market Access Using AI Solutions
4.3.1.1.8. Post-market Surveillance Using AI Solutions
4.3.2. Growing Adoption of RWE In Drug Development and Commercialization
4.3.3. Rising Number of Consolidations
4.3.4. Improved Patient Outcomes and Value Creation from Real-World Evidence
4.4. Case Studies For AI-based RWE Solutions
4.4.1. AI-based RWE Solutions for Medical Device Post-market Studies - Huma.AI (U.S.)
4.4.2. AI-enabled RWE Solutions to Support Clinical Decision-making in Drug Research & Development - Owkin, Inc. (France)
4.4.3. AI-integrated RWE Solutions for Market Access - Medaffcon Oy (Finland)
4.4.4. Leveraging Real-world Data Insights Using AI & Machine Learning Algorithms - Aetion, Inc. (U.S.) & Quinten Health (France)
4.4.5. AI-powered RWE Platform to Track Adverse Events - Data2Life (Israel)
4.4.6. AI-powered RWE Solutions to Predict Patients' Health at Critical Care Units - PHASTAR (U.K.)
4.5. Regulatory Analysis
4.5.1. Overview
4.5.2. North America
4.5.3. Europe
4.5.4. Asia-Pacific
4.5.5. Rest of the World
4.6. Pricing Models (EMR/Genomic/Integrated Datasets)
4.6.1. Overview
4.6.2. Pay Per Patient Record (Volume-based Pricing)
4.6.3. Pay Per Usage (Value-based Pricing)
4.6.4. Annual Subscription
5. Real-World Evidence (RWE) Solutions Market Assessment - by Component
5.1. Overview
5.2. Datasets
5.2.1. Disparate Datasets
5.2.1.1. EMR/EHR/Clinical Data
5.2.1.2. Claims & Billing Data
5.2.1.3. Pharmacy Data
5.2.1.4. Product/Disease Registries Data
5.2.1.5. Genomics Data
5.2.1.6. Other Disparate Datasets
5.2.2. Integrated Datasets
5.3. Consulting & Analytics
6. Real-World Evidence Solutions Market Assessment - by Application
6.1. Overview
6.2. Market Access & Reimbursement/Coverage Decisions
6.3. Drug Development & Approvals
6.3.1. Oncology
6.3.2. Neurology
6.3.3. Immunology
6.3.4. Cardiovascular Diseases
6.3.5. Other Therapeutic Areas
6.4. Post-market Surveillance
6.5. Medical Device Development & Approvals
6.6. Other Applications
7. Real-World Evidence (RWE) Solutions Market Assessment - by End User
7.1. Overview
7.2. Pharmaceutical, Biotechnology, and Medical Device Companies
7.3. Healthcare Payers
7.4. Healthcare Providers
7.5. Other End Users
8. Real-world Evidence Solutions Market Assessment - by geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. U.K.
8.3.2. Germany
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Switzerland
8.3.7. Belgium
8.3.8. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. South Korea
8.4.5. Australia
8.4.6. Taiwan
8.4.7. Singapore
8.4.8. Rest of Asia-Pacific
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America
8.6. Middle East & Africa
9. Competitive Landscape
9.1. Introduction
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis
9.5.1. IQVIA Holdings Inc. (U.S.)
9.5.2. Icon plc (IRELAND)
9.5.3. Thermo Fisher Scientific Inc. (U.S.)
10. Company Profiles
10.1. IQVIA Holdings, Inc.
10.2. Icon plc
10.3. Thermo Fisher Scientific Inc.
10.4. F. Hoffmann-La Roche Ltd
10.5. Oracle Corporation
10.6. Elevance Health, Inc.
10.7. Clinigen Group Plc
10.8. Cognizant Technology Solutions Corporation
10.9. Revvity, Inc.
10.10. SAS Institute Inc.
10.11. Parexel International Corporation
10.12. Healthverity, Inc.
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1 Total Cost Per Study, by Phase and Therapeutic Area (USD Million)
Table 2 Sources of Healthcare Data
Table 3 Number of People aged 65 years or Over, by Region, 2019 vs. 2050 (Million)
Table 4 Strategic Developments of Key Players Related to the Integration of AI into RWE Solutions
Table 5 Real-world Evidence Status in Latin America
Table 6 Observed Indicative Prices of Real-world Data by Type (USD Per Patient Record)
Table 7 Global Real-world Solutions Market, by Component, 2022 - 2031 (USD Million)
Table 8 Global RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 9 Global RWE Datasets Market, by Country/Region, 2022-2031 (USD Million)
Table 10 Global RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 11 Global RWE Disparate Datasets Market, by Country/Region, 2022-2031 (USD Million)
Table 12 Global EMR/EHR/Clinical Data Market, by Country/Region, 2022-2031 (USD Million)
Table 13 Global Claims and Billing Data Market, by Country/Region, 2022-2031 (USD Million)
Table 14 Global Pharmacy Data Market, by Country/Region, 2022-2031 (USD Million)
Table 15 Global Product/Disease Registries Data Market, by Country/Region, 2022-2031 (USD Million)
Table 16 Global Genomics Data Market, by Country/Region, 2022-2031 (USD Million)
Table 17 Global Other Disparate Datasets Market, by Country/Region, 2022-2031 (USD Million)
Table 18 Global RWE Integrated Datasets Market, by Country/Region, 2022-2031 (USD Million)
Table 19 Global RWE Consulting & Analytics market, by Country/Region, 2022-2031 (USD Million)
Table 20 Global Real-world Solutions Market, by Application, 2022-2031 (USD Million)
Table 21 Global RWE Solutions Market for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2022-2031 (USD Million)
Table 22 Global RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 23 Global RWE Solutions Market for Drug Development & Approvals, by Country/Region, 2022-2031 (USD Million)
Table 24 Global RWE Solutions Market for Oncology, by Country/Region, 2022-2031 (USD Million)
Table 25 Global RWE Solutions Market for Neurology, by Country/Region, 2022-2031 (USD Million)
Table 26 Global RWE Solutions Market for Immunology, by Country/Region, 2022-2031 (USD Million)
Table 27 Estimated Medical Costs Associated with Cardiovascular Diseases (2020-2030) (USD Billion)
Table 28 Global RWE Solutions Market for Cardiovascular Diseases, by Country/Region, 2022-2031 (USD Million)
Table 29 Global RWE Solutions Market for Other Therapeutic Areas, by Country/Region, 2022-2031 (USD Million)
Table 30 Global RWE Solutions Market for Post-market Surveillance, by Country/Region, 2022-2031 (USD Million)
Table 31 Global RWE Solutions Market for Medical Device Development & Approvals, by Country/Region, 2022-2031 (USD Million)
Table 32 Global RWE Solutions Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
Table 33 Global Real-world Solutions Market, by End User, 2022 - 2031 (USD Million)
Table 34 Global RWE Solutions Market for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2022-2031 (USD Million)
Table 35 Global RWE Solutions Market for Healthcare Payers, by Country/Region, 2022-2031 (USD Million)
Table 36 Global RWE Solutions Market for Healthcare Providers, by Country/Region, 2022-2031 (USD Million)
Table 37 Global RWE Solutions Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
Table 38 Global RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
Table 39 North America: RWE Solutions Market, by Country, 2022-2031 (USD Million)
Table 40 North America: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 41 North America: RWE Datasets Market, By Type, 2022-2031 (USD Million)
Table 42 North America: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
Table 43 North America: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 44 North America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 45 North America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 46 U.S.: RWE Solutions Market, by component, 2022-2031 (USD Million)
Table 47 U.S.: RWE Datasets Market, By Type, 2022-2031 (USD Million)
Table 48 U.S.: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 49 U.S.: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 50 U.S.: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 51 U.S.: RWE Solution, by End User, 2022-2031 (USD Million)
Table 52 Canada: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 53 Canada: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 54 Canada: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 55 Canada: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 56 Canada: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 57 Canada: RWE Solution, by End User, 2022-2031 (USD Million)
Table 58 EUROPE: RWE solutions Market, by Country/Region, 2022-2031 (USD Million)
Table 59 Europe: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 60 Europe: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 61 Europe: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 62 Europe: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 63 Europe: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 64 Europe: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 65 U.K.: Conferences and Workshops on Real-world Evidence Solutions
Table 66 U.K.: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 67 U.K.: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 68 U.K.: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
Table 69 U.K.: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 70 U.K.: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 71 U.K.: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 72 Conferences, Symposia, and Workshops in Germany
Table 73 Germany: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 74 Germany: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 75 Germany: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 76 Germany: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 77 Germany: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 78 Germany: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 79 France: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 80 France: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 81 France: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 82 France: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 83 France: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 84 France: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 85 Italy: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 86 Italy: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 87 Italy: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 88 Italy: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 89 Italy: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 90 Italy: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 91 Spain: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 92 Spain: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 93 Spain: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 94 Spain: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 95 Spain: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 96 Spain: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 97 Switzerland: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 98 Switzerland: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 99 Switzerland: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 100 Switzerland: RWE solutions Market, by Application, 2022-2031 (USD Million)
Table 101 Switzerland: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 102 Switzerland: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 103 Belgium: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 104 Belgium: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 105 Belgium: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 106 Belgium: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 107 Belgium: RWE Solutions Market For Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 108 Belgium: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 109 Rest of Europe: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 110 Rest of Europe: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 111 Rest of Europe: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 112 Rest of Europe: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 113 Rest of Europe: RWE Solutions Market for Drug Development & Approvals, BY Therapeutic Area, 2022-2031 (USD Million)
Table 114 Rest of Europe: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 115 Asia-Pacific: RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
Table 116 Asia-Pacific: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 117 Asia-Pacific: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 118 Asia-Pacific: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
Table 119 Asia-Pacific: RWE Solutions Market, By Application, 2022-2031 (USD Million)
Table 120 Asia-Pacific: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
Table 121 Asia-Pacific: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 122 Japan: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 123 Japan: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 124 Japan: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 125 Japan: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 126 Japan: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 127 Japan: RWE Solutions Market by End User, 2022-2031 (USD Million)
Table 128 Diversified Real-world Data Sources in China
Table 129 China: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 130 China: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 131 China: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 132 China: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 133 China: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 134 China: RWE Solutions Market by End User, 2022-2031 (USD Million)
Table 135 India: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 136 INDIA: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 137 India: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 138 India: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 139 India: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
Table 140 India: RWE Solutions Market by End User, 2022-2031 (USD Million)
Table 141 South Korea: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 142 South Korea: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 143 South Korea: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 144 South Korea: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 145 South Korea: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
Table 146 South Korea: RWE Solutions Market by End User, 2022-2031 (USD Million)
Table 147 Australia: RWE Solutions Market, By Component, 2022-2031 (USD Million)
Table 148 Australia: RWE Datasets Market, By Type, 2022-2031 (USD Million)
Table 149 Australia: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
Table 150 Australia: RWE Solutions Market, By Application, 2022-2031 (USD Million)
Table 151 Australia: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
Table 152 Australia: RWE Solutions Market by End User, 2022-2031 (USD Million)
Table 153 RWE Sources in Taiwan
Table 154 Taiwan: RWE Solutions Market, By Component, 2022-2031 (USD Million)
Table 155 TAIWAN: RWE Datasets Market, By Type, 2022-2031 (USD Million)
Table 156 Taiwan: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
Table 157 Taiwan: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 158 Taiwan: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
Table 159 Taiwan: RWE Solutions Market by End User, 2022-2031 (USD Million)
Table 160 Currently, the Main Sources for Real-world Data (RWD) in Singapore are:
Table 161 Singapore: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 162 Singapore: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 163 Singapore: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 164 Singapore: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 165 Singapore: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 166 Singapore: RWE Solutions Market by End User, 2022-2031 (USD Million)
Table 167 Estimated Number of New Cancer Cases from 2022 vs 2025
Table 168 rest OF Asia-Pacific: RWE Solutions Market, By Component, 2022-2031 (USD Million)
Table 169 Rest of Asia-Pacific: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 170 Rest of Asia-Pacific: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
Table 171 Rest of Asia-Pacific: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 172 Rest of Asia-Pacific: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
Table 173 Rest of Asia-Pacific: RWE Market for Drug Development & Approvals, By End User, 2022-2031 (USD Million)
Table 174 Latin America: RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
Table 175 Latin America: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 176 Latin America: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 177 Latin America: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 178 Latin America: RWE Solutions Market, by application, 2022-2031 (USD Million)
Table 179 Latin America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 180 Latin America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 181 Brazil: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 182 Brazil: RWE Datasets Market, by Type, 2022-2031 (USD Million)
Table 183 Brazil: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 184 Brazil: RWE Solutions Market, by Application, 2022-2031 (USD Million)
Table 185 Brazil: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 186 Brazil: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 187 Mexico: RWE Solutions Market Size, by Component, 2022-2031 (USD Million)
Table 188 Mexico: RWE Datasets Market Size, by Type, 2022-2031 (USD Million)
Table 189 Mexico: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
Table 190 Mexico: RWE Solutions Market, By Application, 2022-2031 (USD Million)
Table 191 Mexico: RWE Solutions Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
Table 192 Mexico: RWE Market for Drug Development & Approvals, By End User, 2022-2031 (USD Million)
Table 193 Rest of Latin America: RWE Solutions Market, By Component, 2022-2031 (USD Million)
Table 194 Rest of Latin America: RWE Datasets Market, By Type, 2022-2031 (USD Million)
Table 195 Rest of Latin America: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
Table 196 Rest of Latin America: RWE Solutions Market, By Application, 2022-2031 (USD Million)
Table 197 Rest of Latin America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
Table 198 Rest of Latin America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
Table 199 Middle East & Africa: RWE Solutions Market, by Component, 2022-2031 (USD Million)
Table 200 Middle East & Africa: RWE Datasets Market, By Type, 2022-2031 (USD Million)
Table 201 Middle East & Africa: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
Table 202 Middle East & Africa: RWE Solutions Market Size, By Application, 2022-2031 (USD Million)
Table 203 Middle East & Africa: RWE Solutions Market size For Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
Table 204 Middle East & Africa: RWE Solutions Market, By End User, 2022-2031 (USD Million)
Table 205 Recent Developments, By Company, 2021-2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced For This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing & Growth Forecast Approach
Figure 7 Global RWE Solutions Market, By Component, 2024 Vs. 2031 (USD Million)
Figure 8 Global RWE Solutions Market, By Application, 2024 Vs. 2031 (USD Million)
Figure 9 Global RWE Solutions Market, By End User, 2024 Vs. 2031 (USD Million)
Figure 10 RWE Solutions Market, By Geography 2024 Vs. 2031 (USD Million)
Figure 11 Impact Analysis of Market Dynamics
Figure 12 Personalized Medicines Approved of Total New Molecular Entities, 2015-2022 (%)
Figure 13 Share of Clinical Trials Conducted Between 2017-2021, By Region (%)
Figure 14 Global Real-World Solutions Market, By Component, 2024 Vs. 2031 (USD Million)
Figure 15 Global Real-World Solutions Market, By Application, 2024 Vs. 2031 (USD Million)
Figure 16 Global Real-World Solutions Market, By End User, 2024 Vs. 2031 (USD Million)
Figure 17 Global RWE Solutions Market, By Country/Region, 2024 Vs. 2031 (USD Million)
Figure 18 North America: RWE Solutions Market Snapshot
Figure 19 U.S: Number of Novel Drug Approvals (2016-2023)
Figure 20 Europe: RWE Solutions Market Snapshot
Figure 21 France: Share of Population Aged 65 and Above, 2017-2023
Figure 22 Spain: Pharmaceutical R&D Expenditure, 2019-2022 (USD Million)
Figure 23 Switzerland: Pharmaceutical R&D Expenditure, 2019-2022 (USD Million)
Figure 24 Pharmaceutical Production in Belgium, 2019-2022 (USD Million)
Figure 25 Asia-Pacific: Real-World Evidence Solutions Market Snapshot
Figure 26 Latin America: RWE Solutions Market Snapshot
Figure 27 Key Growth Strategies Adopted By Leading Players, 2021-2024
Figure 28 Real-World Evidence (RWE) Solutions Market: Competitive Benchmarking, by Component
Figure 29 Real-World Evidence (RWE) Solutions Market: Competitive Benchmarking, by Region
Figure 30 Competitive Dashboard: Real-World Evidence (RWE) Solutions Market
Figure 31 Market Share Analysis: Real-World Evidence (RWE) Solutions Industry, 2023
Figure 32 IQVIA Holdings, Inc.: Financial Overview (2023)
Figure 33 ICON plc: Financial Overview (2023)
Figure 34 Thermo Fisher Scientific, Inc.: Financial Snapshot (2023)
Figure 35 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2023)
Figure 36 Oracle Corporation: Financial Snapshot (2023)
Figure 37 Elevance Health, Inc.: Financial Overview (2023)
Figure 38 Cognizant Technology Solutions Corporation: Financial Snapshot (2023)
Figure 39 Revvity, Inc.: Financial Snapshot (2023)
Figure 40 SAS Institute Inc.: Financial Snapshot (2023)

Samples

Loading
LOADING...

Companies Mentioned

  • IQVIA Holdings Inc. (U.S.)
  • Elevance Health
  • Inc. (U.S.)
  • ICON plc (Ireland)
  • Clinigen Group plc (U.K.)
  • Cognizant Technology Solutions Corporation (U.S.)
  • Revvity
  • Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Oracle Corporation (U.S.)
  • SAS Institute Inc. (U.S.)
  • Parexel International Corporation (U.S.)
  • and HealthVerity
  • Inc. (U.S.)

Related Topics

Related Reports

Real World Evidence Solutions Market by Component (Services, Disparate Data Sets (Clinical), Application (Drug and Medical Device Development and Approvals), Mode of Deployment, Revenue Model, End-users, & Region, Business Model - Forecast to 2029 - Product Image

Real World Evidence Solutions Market by Component (Services, Disparate Data Sets (Clinical), Application (Drug and Medical Device Development and Approvals), Mode of Deployment, Revenue Model, End-users, & Region, Business Model - Forecast to 2029

  • Report
  • 412 Pages
  • Global
From
Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, Data Sets), Application (Drug Development & Approvals), End-use, Therapeutic Area (Oncology, Cardiology), Region, and Segment Forecasts, 2024-2030 - Product Image

Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, Data Sets), Application (Drug Development & Approvals), End-use, Therapeutic Area (Oncology, Cardiology), Region, and Segment Forecasts, 2024-2030

  • Report
  • 150 Pages
  • Global
From
Real-World Evidence Solutions Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Real-World Evidence Solutions Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Real World Evidence Solution Market by Component, Therapeutic Area, End-User - Global Forecast 2025-2030 - Product Image

Real World Evidence Solution Market by Component, Therapeutic Area, End-User - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Real World Evidence Solutions - Global Strategic Business Report - Product Image

Real World Evidence Solutions - Global Strategic Business Report

  • Report
  • 246 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.